Hormonal agents (18)
Sex hormones (14)
Spiro compounds (5)
Cyclic compounds (3)
Sigma Aldrich (3)
AK Scientific (1)
Oakwood Chemical (1)
TCI Chemicals (1)
Pregnenedione · Progesterone, (13 alpha,17 alpha)-(+-)-Isomer · Progesterone, (9 beta,10 alpha)-Isomer
Progesterone (P4) is an endogenous steroid and progestogen sex hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. It belongs to a group of steroid hormones called the progestogens, and is the major progestogen in the body. Progesterone has a variety of important functions in the body.
Tolvaptan (INN, trade names Samsca and Jinarc) is a selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009, and is sold by Otsuka Pharmaceutical Co.
hydroxyprogesterone (604-09-1, 68-96-2)
17 Hydroxyprogesterone · 17 alpha Hydroxyprogesterone · 17 alpha-Hydroxyprogesterone
Hydroxyprogesterone (OHP) may refer to: 3α-Hydroxyprogesterone (3α-dihydroprogesterone) 3β-Hydroxyprogesterone (3β-dihydroprogesterone) 11α-Hydroxyprogesterone 11β-Hydroxyprogesterone (21-deoxycorticosterone) 16α-Hydroxyprogesterone 17α-Hydroxyprogesterone 20α-Hydroxyprogesterone 21-Hydroxyprogesterone (11-deoxycorticosterone)
Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009.
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
Retroprogesterone, also known as 9β,10α-progesterone or as 9β,10α-pregn-4-ene-3,20-dione, is a synthetic steroid and stereoisomer of the natural progestogen, progesterone. It is the parent compound of a group of progestins consisting of dydrogesterone (6-dehydroretroprogesterone) and trengestone (1,6-bis-dehydro-6-chloro-retroprogesterone). Retroprogesterone itself binds with high affinity to the progesterone receptor as well.
6 beta, 7 beta, 15 beta, 16 beta-dimethylene-1,4-androstadiene-(17(beta-1')-spiro-5')-perhydrofuran-2',3-dione
Spirorenone (INN) (developmental code name ZK-35973) is a steroidal antimineralocorticoid of the spirolactone group that was never marketed. Spirorenone possesses 5–8 times the antimineralocorticoid activity of spironolactone in animal studies. The initial discovery of spirorenone was deemed a great success, as no compound with greater antimineralocorticoid activity had been developed since spironolactone in 1957.
Prorenone (developmental code name SC-23133) is a steroidal antimineralocorticoid of the spirolactone group related to spironolactone that was never marketed. It is the lactonic form of prorenoic acid (prorenoate), and prorenoate potassium (SC-23992), the potassium salt of prorenoic acid, also exists. Prorenoate potassium is about 8 times more potent than spironolactone as an antimineralocorticoid in animals, and it may act as a prodrug to prorenone.
SC-5233, also known as 6,7-dihydrocanrenone or 20-spirox-4-ene-3,20-dione, is a steroidal antimineralocorticoid of the spirolactone group which was developed by G. D. Searle & Company in the 1950s but was never marketed.